Please Wait...

Cardiovascular Safety in Biopharmaceutical Product Development – From QT Prolongation and Beyond

October 16, 2017 - 11:00am (EDT)

Duration: 60 minutes

Featured Speakers:

The cardiac safety ECG environment continues to mature and expand based on scientific advancements and understanding of pathways and systems associated with generating cardiac risk. The most recent ICH-E14 Q&A, and the ensuing cardiac safety conferences and industry meetings, have highlighted the advancements and direction for evaluating the cardiac safety during the drug development process. In addition to the role of ECG data in cardiac safety assessment, there are also considerations related to the "off-target" blood pressure safety signals, which are a consideration from a safety and regulatory perspective.

Objective

The objective and learning goals for the webinar will include:

  • Provide attendees with the background and perspective on the use of QT prolongation as a cardiac safety endpoint within drug development, and take it forward to the more recent discussions beyond the Through QT (TQT)
  • Learning about additional ECG intervals under discussion related to cardiac safety assessment
  • An overview of the discussion around the use of long term ECG capture versus the 10 second ECG signal/waveform in clinical trials
  • Provide a case study approach looking at therapeutic indications/class of compounds that require specific considerations
  • Present background associated with the focus on BP as a cardiovascular safety endpoint in recent years, specific to the off-target blood pressure signal, using a case study review approach for the discussion

Register Now

Jean T. Barbey, MD, Cardiovascular Safety Expert

Dr. Barbey has more than 20 years of experience as a practicing physician, teacher, and clinical researcher in academia and the contract research organization (CRO) industry. He is a fellow of the American College of Cardiology (FACC) and board-certified in internal medicine, clinical pharmacology, cardiovascular disease, and cardiac electrophysiology. He previously served as the medical director at Medifacts International, (now Bioclinica) a global cardiac core laboratory.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will… https://t.co/BX6wzXctMm
bioclinica (2 days ago)
Let's talk oncology clinical trials at #ESMO18 ! Tap the knowledge of medical & scientific experts @bioclinica who'… https://t.co/RlTjGND5Qg
bioclinica (3 days ago)
RT @Xtalks: Fit-for-Future #Pharmacovigilance Sourcing Strategies Join this webinar with @bioclinica for a discussion of the challenges and…
bioclinica (4 days ago)
Bioclinica's Peter Woods leading a talk on fueling the clinical supply chain at Clinical Trial Supply East Coast in… https://t.co/AtXxORQTLE
bioclinica (5 days ago)
Heading to #ESMO18 in search of answers for #oncology clinical trials? Tap the knowledge of Bioclinica medical & sc… https://t.co/YS3jW9Ewd4
bioclinica (5 days ago)
Bioclinica Site Network had a blast at #SCRS18 catching up w Sanofi & so many amazing individuals we are honored to… https://t.co/XkrtEztaRl
bioclinica (6 days ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner